Damiano Venturiello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Damiano Venturiello has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Emiliano Marco Navarra
Department of Cardiac Surgery, San Carlo di Nancy Hospital, GVM Care & Research, 00165 Rome, Italy
2 shared publications - Giuseppe Campolongo
Department of Cardiac Surgery, San Carlo di Nancy Hospital, GVM Care & Research, 00165 Rome, Italy
2 shared publications - Giuseppe Speziale
Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70124 Bari, Italy
2 shared publications - Walter Vignaroli
Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70124 Bari, Italy
2 shared publications - Alessandro Cianca
Cardiology, Clinical and Molecular Medicine Department, Sapienza University of Rome, 00189 Rome, Italy
1 shared publication - Beatrice Musumeci
Cardiology Unit, Department of Clinical and Molecular Medicine, Sant’Andrea University Hospital, Sapienza University, 00189 Rome, Italy
1 shared publication
Latest Publications
- Open Access
- 9 July 2026
- Published by BMJ in Open Heart
- Vol. 13 (2) , e004211
AI-enhanced electrocardiography as a digital biomarker platform in cardiovascular medicine: clinical applications, validation gaps and future implementation pathways
Artificial intelligence applied to the ECG is expanding the clinical role of this widely available diagnostic tool beyond conventional waveform interpretation by enabling identification of electrophysiological patterns associated with cardiovascular structure, function and risk. Within this evolving framework, the artificial intelligence enhanced ECG is emerging as a scalable digital biomarker platform supporting screening, diagnosis and prognostic stratification across the cardiovascular disease continuum. This narrative review synthesises current evidence on the clinical applications of artificial intelligence enhanced ECG, including detection of cardiac rhythm disorders, early identification of structural heart disease, decision support in acute coronary syndromes, prediction of clinical outcomes and population level cardiovascular screening using wearable technologies. Deep learning models applied to standard and simplified electrocardiographic recordings demonstrate strong diagnostic performance in identifying atrial fibrillation, left ventricular dysfunction, hypertrophic cardiomyopathy, cardiac amyloidosis and heart failure with preserved ejection fraction. These approaches also enable estimation of long-term cardiovascular risk from apparently normal tracings and support identification of disease patterns extending beyond overt cardiac conditions. Despite these advances, clinical implementation remains limited by the need for prospective multicentre validation, improved model interpretability, standardised evaluation strategies and integration into routine clinical workflows. This review highlights current validation gaps and outlines key opportunities for translation of artificial intelligence-enhanced ECG into digital cardiology practice.
- 9 July 2026
- Published by BMJ in Open Heart
- Vol. 13 (2) , e004211
Open AccessAI-enhanced electrocardiography as a digital biomarker platform in cardiovascular medicine: clinical applications, validation gaps and future implementation pathways
Artificial intelligence applied to the ECG is expanding the clinical role of this widely available diagnostic tool beyond conventional waveform interpretation by enabling identification of electrophysiological patterns associated with cardiovascular structure, function and risk. Within this evolving framework, the artificial intelligence enhanced ECG is emerging as a scalable digital biomarker platform supporting screening, diagnosis and prognostic stratification across the cardiovascular disease continuum. This narrative review synthesises current evidence on the clinical applications of artificial intelligence enhanced ECG, including detection of cardiac rhythm disorders, early identification of structural heart disease, decision support in acute coronary syndromes, prediction of clinical outcomes and population level cardiovascular screening using wearable technologies. Deep learning models applied to standard and simplified electrocardiographic recordings demonstrate strong diagnostic performance in identifying atrial fibrillation, left ventricular dysfunction, hypertrophic cardiomyopathy, cardiac amyloidosis and heart failure with preserved ejection fraction. These approaches also enable estimation of long-term cardiovascular risk from apparently normal tracings and support identification of disease patterns extending beyond overt cardiac conditions. Despite these advances, clinical implementation remains limited by the need for prospective multicentre validation, improved model interpretability, standardised evaluation strategies and integration into routine clinical workflows. This review highlights current validation gaps and outlines key opportunities for translation of artificial intelligence-enhanced ECG into digital cardiology practice.
- Open Access
- 3 July 2026
- Published by Elsevier in JACC: Case Reports
- p. 109207
Interpreting Serial AI-ECG Changes During Heart Failure Therapy
- 3 July 2026
- Published by Elsevier in JACC: Case Reports
- p. 109207
Open AccessInterpreting Serial AI-ECG Changes During Heart Failure Therapy
- Open Access
- 24 June 2026
- Published by MDPI AG in Preprints.org
Stress-Related Blood Pressure Surges and Labile Hypertension: A Neurocardiovascular Phenotype Across the Continuum of Cardiovascular Risk
Transient stress-related blood pressure elevations are common in clinical practice, particularly among individuals with anxiety traits, autonomic hyperreactivity, or adverse psychosocial exposure, yet their prognostic significance and management remain unclear. While blood pressure variability is increasingly recognised as an independent cardiovascular risk factor, episodic hypertensive peaks are often considered benign when baseline office or ambulatory blood pressure values are normal. However, recurrent blood pressure surges may contribute to cumulative vascular and organ damage through repeated pulsatile stress, endothelial dysfunction, and transient increases in left ventricular afterload, whereas unnecessary antihypertensive therapy may induce hypotension during inter-episode periods.Psychological stress, anxiety disorders, trauma-related syndromes, and autonomic dysregulation can trigger transient blood pressure elevations via sympathetic activation, hypothalamic-pituitary-adrenal axis stimulation, central renin-angiotensin signalling, and impaired baroreflex control. Repeated neurohormonal activation may progressively impair vascular function and facilitate the transition from reactive blood pressure elevations to sustained hypertension. Increased blood pressure variability has been associated with target organ damage, cardiovascular events, stroke, renal dysfunction, and mortality independently of mean blood pressure levels. Similarly, exaggerated blood pressure responses to mental stress have been linked to incident hypertension and subclinical cardiac remodelling, even in normotensive individuals. This review interprets stress-related blood pressure surges and labile hypertension as a neurocardiovascular phenotype along the continuum from normotension to established hypertension. Current evidence on pathophysiology, cardiovascular implications, diagnosis, and therapeutic strategies is summarised, highlighting the need for phenotype-based assessment and prospective studies to define long-term risk and optimal management.
- 24 June 2026
- Published by MDPI AG in Preprints.org
Open AccessStress-Related Blood Pressure Surges and Labile Hypertension: A Neurocardiovascular Phenotype Across the Continuum of Cardiovascular Risk
Transient stress-related blood pressure elevations are common in clinical practice, particularly among individuals with anxiety traits, autonomic hyperreactivity, or adverse psychosocial exposure, yet their prognostic significance and management remain unclear. While blood pressure variability is increasingly recognised as an independent cardiovascular risk factor, episodic hypertensive peaks are often considered benign when baseline office or ambulatory blood pressure values are normal. However, recurrent blood pressure surges may contribute to cumulative vascular and organ damage through repeated pulsatile stress, endothelial dysfunction, and transient increases in left ventricular afterload, whereas unnecessary antihypertensive therapy may induce hypotension during inter-episode periods.Psychological stress, anxiety disorders, trauma-related syndromes, and autonomic dysregulation can trigger transient blood pressure elevations via sympathetic activation, hypothalamic-pituitary-adrenal axis stimulation, central renin-angiotensin signalling, and impaired baroreflex control. Repeated neurohormonal activation may progressively impair vascular function and facilitate the transition from reactive blood pressure elevations to sustained hypertension. Increased blood pressure variability has been associated with target organ damage, cardiovascular events, stroke, renal dysfunction, and mortality independently of mean blood pressure levels. Similarly, exaggerated blood pressure responses to mental stress have been linked to incident hypertension and subclinical cardiac remodelling, even in normotensive individuals. This review interprets stress-related blood pressure surges and labile hypertension as a neurocardiovascular phenotype along the continuum from normotension to established hypertension. Current evidence on pathophysiology, cardiovascular implications, diagnosis, and therapeutic strategies is summarised, highlighting the need for phenotype-based assessment and prospective studies to define long-term risk and optimal management.
- Open Access
- 13 April 2026
- Published by MDPI AG in Preprints.org
AI–Enhanced Electrocardiography as a Digital Biomarker Platform in Cardiovascular Medicine
In recent years, Artificial Intelligence (AI) applied to the electrocardiogram (ECG) has shown increasing potential in improving diagnosis, prognostic stratification, and cardiovascular screening through the identification of electrophysiological patterns not detectable with conventional interpretation. This narrative review, incorporating elements of a scoping review, summarizes the main available evidence on the use of AI-ECG across the entire continuum of cardiovascular disease, including arrhythmia detection, early identification of structural heart disease, decision support in acute coronary syndromes, prediction of clinical outcomes, and applications in population screening using wearable devices. Deep learning models applied to both the standard 12-lead ECG and simplified re-cordings have demonstrated high diagnostic performance in identifying atrial fibrillation (AF), left ventricle (LV) dysfunction, hypertrophic cardiomyopathy (HCM), cardiac amyloidosis, and heart failure with preserved ejection fraction (HFpEF), as well as a potential role in cardiovascular risk stratification and in the identification of systemic digital biomarkers. Despite these promising results, the clinical adoption of AI-ECG is still limited by the need for prospective multicenter validation and by challenges related to model interpretability and their integration into clinical workflows. Overall, AI-ECG represents an emerging diagnostic platform with potential applications in predictive, preventive, and personalized cardiology.
- 13 April 2026
- Published by MDPI AG in Preprints.org
Open AccessAI–Enhanced Electrocardiography as a Digital Biomarker Platform in Cardiovascular Medicine
In recent years, Artificial Intelligence (AI) applied to the electrocardiogram (ECG) has shown increasing potential in improving diagnosis, prognostic stratification, and cardiovascular screening through the identification of electrophysiological patterns not detectable with conventional interpretation. This narrative review, incorporating elements of a scoping review, summarizes the main available evidence on the use of AI-ECG across the entire continuum of cardiovascular disease, including arrhythmia detection, early identification of structural heart disease, decision support in acute coronary syndromes, prediction of clinical outcomes, and applications in population screening using wearable devices. Deep learning models applied to both the standard 12-lead ECG and simplified re-cordings have demonstrated high diagnostic performance in identifying atrial fibrillation (AF), left ventricle (LV) dysfunction, hypertrophic cardiomyopathy (HCM), cardiac amyloidosis, and heart failure with preserved ejection fraction (HFpEF), as well as a potential role in cardiovascular risk stratification and in the identification of systemic digital biomarkers. Despite these promising results, the clinical adoption of AI-ECG is still limited by the need for prospective multicenter validation and by challenges related to model interpretability and their integration into clinical workflows. Overall, AI-ECG represents an emerging diagnostic platform with potential applications in predictive, preventive, and personalized cardiology.
- Open Access
Atrial Secondary Mitral Regurgitation: Pathophysiology, Diagnosis, and Surgical Implications
Background and Objectives: Atrial secondary mitral regurgitation (A-SMR), also referred to as atrial functional mitral regurgitation, has emerged as a distinct clinical phenotype characterized by left atrial enlargement, mitral annular dilatation, and preserved left ventricular geometry and systolic function. Frequently associated with long-standing atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF), A-SMR challenges the traditional ventricular-centered classification of functional mitral regurgitation (MR) and is increasingly recognized as a clinically relevant condition. Materials and Methods: This narrative review provides an updated and critical overview of current evidence on A-SMR. We summarize available data on pathophysiology, diagnostic imaging, natural history, and therapeutic strategies, with particular emphasis on implications for cardiac surgery and clinical decision-making. Evidence was derived from observational studies, registry analyses, interventional reports, and contemporary guideline documents. Results: A-SMR is primarily driven by atrial remodeling and annular dilatation, with minimal contribution from ventricular distortion or leaflet tethering. Echocardiography and Magnetic Resonance Imaging (MRI) play a central role in diagnosis and phenotypic characterization, allowing differentiation from ventricular functional MR and identification of distinct A-SMR subtypes with potential therapeutic implications. A-SMR is a progressive condition associated with worsening symptoms and adverse clinical outcomes. Rhythm control strategies may reduce MR severity in selected patients by promoting atrial reverse remodeling. Transcatheter edge-to-edge repair (TEER) represents a treatment option for selected high-risk patients, although concerns regarding long-term durability remain in this predominantly annular disease. From a pathophysiological standpoint, surgical mitral valve repair based on annuloplasty directly targets the dominant mechanism of A-SMR and has been associated with favorable outcomes in appropriately selected patients. Conclusions: A-SMR is a distinct and increasingly recognized form of functional MR requiring a mechanism-oriented diagnostic and therapeutic approach. The 2025 ESC/EACTS Guidelines for the management of valvular heart disease have acknowledged A-SMR as a specific clinical phenotype, although dedicated phenotype-specific management recommendations remain limited. Surgical mitral valve repair, particularly when combined with AF ablation, represents a rational treatment strategy in selected patients and may improve long-term outcomes.
Open AccessAtrial Secondary Mitral Regurgitation: Pathophysiology, Diagnosis, and Surgical Implications
Background and Objectives: Atrial secondary mitral regurgitation (A-SMR), also referred to as atrial functional mitral regurgitation, has emerged as a distinct clinical phenotype characterized by left atrial enlargement, mitral annular dilatation, and preserved left ventricular geometry and systolic function. Frequently associated with long-standing atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF), A-SMR challenges the traditional ventricular-centered classification of functional mitral regurgitation (MR) and is increasingly recognized as a clinically relevant condition. Materials and Methods: This narrative review provides an updated and critical overview of current evidence on A-SMR. We summarize available data on pathophysiology, diagnostic imaging, natural history, and therapeutic strategies, with particular emphasis on implications for cardiac surgery and clinical decision-making. Evidence was derived from observational studies, registry analyses, interventional reports, and contemporary guideline documents. Results: A-SMR is primarily driven by atrial remodeling and annular dilatation, with minimal contribution from ventricular distortion or leaflet tethering. Echocardiography and Magnetic Resonance Imaging (MRI) play a central role in diagnosis and phenotypic characterization, allowing differentiation from ventricular functional MR and identification of distinct A-SMR subtypes with potential therapeutic implications. A-SMR is a progressive condition associated with worsening symptoms and adverse clinical outcomes. Rhythm control strategies may reduce MR severity in selected patients by promoting atrial reverse remodeling. Transcatheter edge-to-edge repair (TEER) represents a treatment option for selected high-risk patients, although concerns regarding long-term durability remain in this predominantly annular disease. From a pathophysiological standpoint, surgical mitral valve repair based on annuloplasty directly targets the dominant mechanism of A-SMR and has been associated with favorable outcomes in appropriately selected patients. Conclusions: A-SMR is a distinct and increasingly recognized form of functional MR requiring a mechanism-oriented diagnostic and therapeutic approach. The 2025 ESC/EACTS Guidelines for the management of valvular heart disease have acknowledged A-SMR as a specific clinical phenotype, although dedicated phenotype-specific management recommendations remain limited. Surgical mitral valve repair, particularly when combined with AF ablation, represents a rational treatment strategy in selected patients and may improve long-term outcomes.
- Open Access
- 5 February 2026
- Published by MDPI AG in Preprints.org
Atrial Secondary Mitral Regurgitation: Pathophysiology, Diagnosis, and Surgical Implications
Background and Objectives Atrial secondary mitral regurgitation (A-SMR), also referred to as atrial functional mitral regurgitation, has emerged as a distinct clinical phenotype characterized by left atrial enlargement, mitral annular dilatation, and preserved left ventricular geometry and systolic function [1]. Frequently associated with long-standing atrial fibrillation and heart failure with preserved ejection fraction, A-SMR challenges the traditional ventricular-centered classification of functional mitral regurgitation and is increasingly recognized as a clinically relevant condition [2,3]. Materials and Methods This narrative review provides an updated and critical overview of cur-rent evidence on atrial secondary mitral regurgitation. We summarize available data on pathophysiology, diagnostic imaging, natural history, and therapeutic strategies, with particular emphasis on implications for cardiac surgery and clinical decision-making. Evidence was derived from observational studies, registry analyses, interventional reports, and contemporary guideline documents [4,5]. Results A-SMR is primarily driven by atrial remodeling and annular dilatation, with minimal contribution from ventricular distortion or leaflet tethering [1,3]. Echocardiography and Magnetic Resonance Imaging (MRI) play a central role in diagnosis and phenotypic characterization, allowing differentiation from ventricular functional mitral regurgitation and identification of distinct A-SMR subtypes with potential therapeutic implications [4]. A-SMR is a progressive condition associated with worsening symptoms and adverse clinical outcomes [2,3]. Rhythm control strategies may reduce mitral regurgitation severity in selected patients by promo-ting atrial reverse remodeling [6]. Transcatheter edge-to-edge repair (TEER) represents a treatment option for selected high-risk patients, al-though concerns regarding long-term durability remain in this predominantly annular disease [7]. From a pathophysiological standpoint, surgical mitral valve repair based on annuloplasty directly targets the dominant mechanism of A-SMR and has been associated with favorable outcomes in appropriately selected patients [8]. Conclusions Atrial secondary mitral regurgitation is a distinct and increasingly re-cognized form of functional mitral regurgitation requiring a mechanism-oriented diagnostic and therapeutic approach. 2025 ESC/EACTS Guidelines for the management of valvular heart disease have acknowledged A-SMR as a specific clinical phenotype, although dedicated phenotype-specific management recommendations remain limited [5]. Surgical mitral valve repair, particularly when combined with atrial fibrillation ablation, represents a rational treatment strategy in selected patients and may improve long-term outcomes [6,8].
- 5 February 2026
- Published by MDPI AG in Preprints.org
Open AccessAtrial Secondary Mitral Regurgitation: Pathophysiology, Diagnosis, and Surgical Implications
Background and Objectives Atrial secondary mitral regurgitation (A-SMR), also referred to as atrial functional mitral regurgitation, has emerged as a distinct clinical phenotype characterized by left atrial enlargement, mitral annular dilatation, and preserved left ventricular geometry and systolic function [1]. Frequently associated with long-standing atrial fibrillation and heart failure with preserved ejection fraction, A-SMR challenges the traditional ventricular-centered classification of functional mitral regurgitation and is increasingly recognized as a clinically relevant condition [2,3]. Materials and Methods This narrative review provides an updated and critical overview of cur-rent evidence on atrial secondary mitral regurgitation. We summarize available data on pathophysiology, diagnostic imaging, natural history, and therapeutic strategies, with particular emphasis on implications for cardiac surgery and clinical decision-making. Evidence was derived from observational studies, registry analyses, interventional reports, and contemporary guideline documents [4,5]. Results A-SMR is primarily driven by atrial remodeling and annular dilatation, with minimal contribution from ventricular distortion or leaflet tethering [1,3]. Echocardiography and Magnetic Resonance Imaging (MRI) play a central role in diagnosis and phenotypic characterization, allowing differentiation from ventricular functional mitral regurgitation and identification of distinct A-SMR subtypes with potential therapeutic implications [4]. A-SMR is a progressive condition associated with worsening symptoms and adverse clinical outcomes [2,3]. Rhythm control strategies may reduce mitral regurgitation severity in selected patients by promo-ting atrial reverse remodeling [6]. Transcatheter edge-to-edge repair (TEER) represents a treatment option for selected high-risk patients, al-though concerns regarding long-term durability remain in this predominantly annular disease [7]. From a pathophysiological standpoint, surgical mitral valve repair based on annuloplasty directly targets the dominant mechanism of A-SMR and has been associated with favorable outcomes in appropriately selected patients [8]. Conclusions Atrial secondary mitral regurgitation is a distinct and increasingly re-cognized form of functional mitral regurgitation requiring a mechanism-oriented diagnostic and therapeutic approach. 2025 ESC/EACTS Guidelines for the management of valvular heart disease have acknowledged A-SMR as a specific clinical phenotype, although dedicated phenotype-specific management recommendations remain limited [5]. Surgical mitral valve repair, particularly when combined with atrial fibrillation ablation, represents a rational treatment strategy in selected patients and may improve long-term outcomes [6,8].
- Top Cited PapersOpen Access
- 23 January 2026
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 69 (1) , 1-7
Bridging the heart–mind divide: Psychiatric implementation of the 2025 ESC mental–CVD consensus
The 2025 ESC (European Society of Cardiology) Clinical Consensus Statement on mental health and cardiovascular disease is a milestone for psychiatry as much as for cardiology. It recognizes mental disorders as major determinants of cardiovascular (CV) risk and explicitly calls for collaboration with the European Psychiatric Association (EPA). In parallel, the EPA Presidential Action Plan and its “Whole Person Health” task force promote lifestyle‑based, multimorbidity-focused care. From a psychiatric perspective, the challenge is now to translate these frameworks into everyday practice. In this Viewpoint, we propose three priorities. First, severe mental illness (SMI) and cardiac disease-induced post-traumatic stress disorder (CDI-PTSD) should be treated as high‑risk conditions that trigger proactive CV assessment and structured follow‑up. Second, mental‑health services should adopt a simple “safety bundle” for psychotropic medications in people with, or at high risk of, CV disease. Third, psychiatrists should use cardiac rehabilitation, structured physical activity and social prescribing as psychiatric interventions.
- 23 January 2026
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 69 (1) , 1-7
Top Cited PapersOpen AccessBridging the heart–mind divide: Psychiatric implementation of the 2025 ESC mental–CVD consensus
The 2025 ESC (European Society of Cardiology) Clinical Consensus Statement on mental health and cardiovascular disease is a milestone for psychiatry as much as for cardiology. It recognizes mental disorders as major determinants of cardiovascular (CV) risk and explicitly calls for collaboration with the European Psychiatric Association (EPA). In parallel, the EPA Presidential Action Plan and its “Whole Person Health” task force promote lifestyle‑based, multimorbidity-focused care. From a psychiatric perspective, the challenge is now to translate these frameworks into everyday practice. In this Viewpoint, we propose three priorities. First, severe mental illness (SMI) and cardiac disease-induced post-traumatic stress disorder (CDI-PTSD) should be treated as high‑risk conditions that trigger proactive CV assessment and structured follow‑up. Second, mental‑health services should adopt a simple “safety bundle” for psychotropic medications in people with, or at high risk of, CV disease. Third, psychiatrists should use cardiac rehabilitation, structured physical activity and social prescribing as psychiatric interventions.
- Open Access
- 16 October 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (37) , 105670
Giant Aneurysm in a Circumflex Coronary Sinus Fistula
- 16 October 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (37) , 105670
Open AccessGiant Aneurysm in a Circumflex Coronary Sinus Fistula
- Open Access
- 6 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (23) , 13147
Unveiling the Future of Cardiac Care: A Review of Gene Therapy in Cardiomyopathies
For years, the treatment of many cardiomyopathies has been solely focused on symptom management. However, cardiomyopathies have a genetic substrate, and directing therapy towards the pathophysiology rather than the epiphenomenon of the disease may be a winning strategy. Gene therapy involves the insertion of genes or the modification of existing ones and their regulatory elements through strategies like gene replacement and gene editing. Recently, gene therapy for cardiac amyloidosis and Duchenne muscular dystrophy has received approval, and important clinical trials are currently evaluating gene therapy methods for rare heart diseases like Friedreich’s Ataxia, Danon disease, Fabry disease, and Pompe Disease. Furthermore, favorable results have been noted in animal studies receiving gene therapy for hypertrophic, dilated, and arrhythmogenic cardiomyopathy. This review discusses gene therapy methods, ongoing clinical trials, and future goals in this area.
- 6 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (23) , 13147
Open AccessUnveiling the Future of Cardiac Care: A Review of Gene Therapy in Cardiomyopathies
For years, the treatment of many cardiomyopathies has been solely focused on symptom management. However, cardiomyopathies have a genetic substrate, and directing therapy towards the pathophysiology rather than the epiphenomenon of the disease may be a winning strategy. Gene therapy involves the insertion of genes or the modification of existing ones and their regulatory elements through strategies like gene replacement and gene editing. Recently, gene therapy for cardiac amyloidosis and Duchenne muscular dystrophy has received approval, and important clinical trials are currently evaluating gene therapy methods for rare heart diseases like Friedreich’s Ataxia, Danon disease, Fabry disease, and Pompe Disease. Furthermore, favorable results have been noted in animal studies receiving gene therapy for hypertrophic, dilated, and arrhythmogenic cardiomyopathy. This review discusses gene therapy methods, ongoing clinical trials, and future goals in this area.